




Searching News Database: ovarian cancer
HSMN NewsFeed - 31 Dec 2024
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
HSMN NewsFeed - 8 Jul 2021
Theolytics expands Series A financing and welcomes M Ventures as a new investor
Theolytics expands Series A financing and welcomes M Ventures as a new investor
HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
HSMN NewsFeed - 13 Jan 2020
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
HSMN NewsFeed - 24 Jun 2019
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
HSMN NewsFeed - 28 Sep 2018
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
HSMN NewsFeed - 27 Mar 2017
Bovie Medical Receives 510K Clearance for Its Cool-Coag(TM) Generator and Open Handpiece
Bovie Medical Receives 510K Clearance for Its Cool-Coag(TM) Generator and Open Handpiece
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 31 Oct 2016
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
HSMN NewsFeed - 10 Jun 2016
AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development
AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development
HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
HSMN NewsFeed - 26 Jan 2016
Abcodia Announces Expanded U.S. Availability of the ROCA(R) Test for Early Ovarian Cancer Detection
Abcodia Announces Expanded U.S. Availability of the ROCA(R) Test for Early Ovarian Cancer Detection
HSMN NewsFeed - 19 Nov 2015
Oncimmune Appoints Dr James Jett, World Recognised Lung Cancer Specialist, as Chief Medical Officer
Oncimmune Appoints Dr James Jett, World Recognised Lung Cancer Specialist, as Chief Medical Officer
HSMN NewsFeed - 19 Oct 2015
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
HSMN NewsFeed - 20 Jun 2014
ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing
ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing
HSMN NewsFeed - 2 Jun 2014
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
HSMN NewsFeed - 26 Aug 2013
GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer
GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer
HSMN NewsFeed - 24 Jul 2013
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
HSMN NewsFeed - 12 Jun 2013
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
HSMN NewsFeed - 23 Apr 2013
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
HSMN NewsFeed - 13 Mar 2013
Vermillion Appoints Thomas McLain as President and Chief Executive Officer
Vermillion Appoints Thomas McLain as President and Chief Executive Officer
HSMN NewsFeed - 12 Nov 2012
Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 11 Oct 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
HSMN NewsFeed - 15 Jun 2011
Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs
Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs
HSMN NewsFeed - 9 Jun 2011
Northwest Biotherapeutics Announces Change and Expansion of Management Team
Northwest Biotherapeutics Announces Change and Expansion of Management Team
HSMN NewsFeed - 31 May 2011
Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer
Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer
HSMN NewsFeed - 14 Mar 2011
Mira Dx(TM) Dismisses Flawed Study as “Puzzling,” and “Comparing Apples and Oranges”
Mira Dx(TM) Dismisses Flawed Study as “Puzzling,” and “Comparing Apples and Oranges”
HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
HSMN NewsFeed - 5 Jan 2011
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
HSMN NewsFeed - 21 Apr 2010
Manhattan Scientifics' Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram
Manhattan Scientifics' Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram
HSMN NewsFeed - 17 Mar 2010
New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer
New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer
HSMN NewsFeed - 25 Feb 2010
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
HSMN NewsFeed - 14 Jan 2010
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
HSMN NewsFeed - 29 Jul 2009
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
HSMN NewsFeed - 27 Jul 2009
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
HSMN NewsFeed - 23 Jul 2009
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
HSMN NewsFeed - 15 Jul 2009
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
HSMN NewsFeed - 24 Mar 2009
Myriad Applauds New ACOG Guidelines for Hereditary Breast and Ovarian Cancer
Myriad Applauds New ACOG Guidelines for Hereditary Breast and Ovarian Cancer
HSMN NewsFeed - 19 Feb 2009
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
HSMN NewsFeed - 12 Jan 2009
Hana Biosciences Appoints Thomas J. Tarlow as Vice President, Regulatory Affairs and Quality
Hana Biosciences Appoints Thomas J. Tarlow as Vice President, Regulatory Affairs and Quality
HSMN NewsFeed - 16 Dec 2008
Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
HSMN NewsFeed - 16 Dec 2008
Generex Biotechnology and Pevion Biotech Announce Plans for Immunotherapeutic Vaccine Collaboration
Generex Biotechnology and Pevion Biotech Announce Plans for Immunotherapeutic Vaccine Collaboration
HSMN NewsFeed - 22 Oct 2008
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 3 Sep 2008
Access Pharmaceuticals Retains Piper Jaffray to Augment Strategic Partnering Efforts
Access Pharmaceuticals Retains Piper Jaffray to Augment Strategic Partnering Efforts
HSMN NewsFeed - 16 Jul 2008
Predictive Biosciences Expands Executive Leadership Team with Two Diagnostic Industry Veteran Appointments
Predictive Biosciences Expands Executive Leadership Team with Two Diagnostic Industry Veteran Appointments
HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
HSMN NewsFeed - 16 Apr 2008
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
HSMN NewsFeed - 13 Mar 2008
Novelos Therapeutics Reaches Target Enrollment in Pivotal Phase 3 Lung Cancer Trial
Novelos Therapeutics Reaches Target Enrollment in Pivotal Phase 3 Lung Cancer Trial
HSMN NewsFeed - 8 Mar 2008
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
HSMN NewsFeed - 19 Feb 2008
diaDexus Receives FDA Clearance for Automated Blood Test That Identifies Stroke & Heart Attack Risk
diaDexus Receives FDA Clearance for Automated Blood Test That Identifies Stroke & Heart Attack Risk
HSMN NewsFeed - 13 Feb 2008
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
HSMN NewsFeed - 31 Dec 2007
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
HSMN NewsFeed - 25 Dec 2007
Breast Cancer Gene Mutation More Common in Hispanic, Young Black Women, Stanford/NCCC Study Finds
Breast Cancer Gene Mutation More Common in Hispanic, Young Black Women, Stanford/NCCC Study Finds
HSMN NewsFeed - 12 Nov 2007
VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
HSMN NewsFeed - 29 Oct 2007
European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
HSMN NewsFeed - 29 Oct 2007
ChemGenex Announces Strategic Restructuring of Company to Focus on Late-Stage Cancer Portfolio
ChemGenex Announces Strategic Restructuring of Company to Focus on Late-Stage Cancer Portfolio
HSMN NewsFeed - 22 Oct 2007
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
HSMN NewsFeed - 16 Oct 2007
ViRexx Announces Second OvaRex(R) MAb Phase III Trial Reaches 118th Relapse Event
ViRexx Announces Second OvaRex(R) MAb Phase III Trial Reaches 118th Relapse Event
HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
HSMN NewsFeed - 8 Oct 2007
Immersion Medical Introduces OB/GYN Module for LaparoscopyVR(TM) Surgical Simulator
Immersion Medical Introduces OB/GYN Module for LaparoscopyVR(TM) Surgical Simulator
HSMN NewsFeed - 19 Sep 2007
Novelos Therapeutics Elects Dr. Stephen Hill to Serve as Chairman of Board of Directors
Novelos Therapeutics Elects Dr. Stephen Hill to Serve as Chairman of Board of Directors
HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
HSMN NewsFeed - 30 Aug 2007
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
HSMN NewsFeed - 27 Aug 2007
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
HSMN NewsFeed - 4 Jul 2007
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics
HSMN NewsFeed - 19 Jun 2007
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
HSMN NewsFeed - 3 Jun 2007
Next Generation of Investigational Anti-Cancer Agents Unveiled at ASCO by AstraZeneca
Next Generation of Investigational Anti-Cancer Agents Unveiled at ASCO by AstraZeneca
HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
HSMN NewsFeed - 15 May 2007
Ciphergen Appoints Steve Lundy as Senior Vice President of Sales and Marketing
Ciphergen Appoints Steve Lundy as Senior Vice President of Sales and Marketing
HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
HSMN NewsFeed - 27 Apr 2007
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial Sites
Access Pharmaceuticals Announces Expansion of ProLindac(TM) Clinical Trial Sites
HSMN NewsFeed - 25 Apr 2007
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
HSMN NewsFeed - 19 Apr 2007
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
HSMN NewsFeed - 9 Mar 2007
Ortho Biotech Revises Prescribing Information for PROCRIT(R) (Epoetin alfa)
Ortho Biotech Revises Prescribing Information for PROCRIT(R) (Epoetin alfa)
HSMN NewsFeed - 21 Feb 2007
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
HSMN NewsFeed - 12 Feb 2007
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
HSMN NewsFeed - 26 Dec 2006
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
HSMN NewsFeed - 13 Dec 2006
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
HSMN NewsFeed - 16 Oct 2006
IP Chemotherapy, Combination Therapy for Cervical Cancer and IVF Treatment for Infertility
IP Chemotherapy, Combination Therapy for Cervical Cancer and IVF Treatment for Infertility
HSMN NewsFeed - 27 Sep 2006
Final data from Antisoma's AS1404 lung cancer trial show clear survival benefit
Final data from Antisoma's AS1404 lung cancer trial show clear survival benefit
HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
HSMN NewsFeed - 28 Jun 2006
Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale
Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale
HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed - 1 Jun 2006
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
HSMN NewsFeed - 30 May 2006
Novelos Therapeutics Finalizes SPA with FDA for Phase 3 Trial in Lung Cancer
Novelos Therapeutics Finalizes SPA with FDA for Phase 3 Trial in Lung Cancer
HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
HSMN NewsFeed - 15 May 2006
Advaxis Continues Advancement of Two Listeria Vaccines Targeting Cancers Affecting Women
Advaxis Continues Advancement of Two Listeria Vaccines Targeting Cancers Affecting Women
HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Additional items found! 278

Members Archive contains
278 additional stories matching:
ovarian cancer
(Password required)
ovarian cancer
(Password required)